Skip to main content
. 2022 Jun 20;149(5):1765–1775. doi: 10.1007/s00432-022-04108-9

Table 3.

Univariable and multivariable Cox regression analyses for overall survival

Univariable analysis Multivariable analysis
Hazard ratio P value Hazard ratio P value
Age 1.05 (1.00–1.10) 0.053
Sex
 Male 1.00 (Reference)
 Female 1.01 (0.49–2.08) 0.979
Adjuvant therapy
 mFOLFIRINOX 1.00 (Reference) 1.00 (Reference)
 Other adjuvants 2.87 (1.22–6.77) 0.016 2.91 (1.24–6.81) 0.014
Re-staged resectability
 RPC 1.00 (Reference)
 BRPC 2.37 (0.82–6.89) 0.112
 LAPC 4.43 (0.78–25.26) 0.093
Post-treatment CA 19–9
  < 37 U/mL 1.00 (Reference) 1.00 (Reference)
  ≥ 37 U/mL 2.29 (1.11–4.73) 0.026 2.39 (1.14–5.03) 0.021
Tumor size (ypT)
  < 2 cm 1.00 (Reference)
 ≥ 2 cm 2.34 (0.80–6.84) 0.119
LN metastasis (ypN)
 Negative (N0) 1.00 (Reference) 1.00 (Reference)
 Positive (N1 or N2) 2.42 (1.07–5.49) 0.034 1.93 (0.84–4.41) 0.121
Resection margin
 Negative 1.00 (Reference)
 Positive 1.17 (0.50–2.75) 0.713
CAP score
 1 1.00 (Reference)
 2 1.91 (0.25–14.48) 0.534
 3 5.78 (0.74–45.35) 0.095

Values in parentheses are 95 per cent confidence intervals. Variables with P < 0.05 in univariable analysis were included in the multivariable model

mFOLFIRINOX modified FOLFIRINOX, BRPC borderline resectable pancreatic cancer, LAPC locally advanced pancreatic cancer, RPC resectable pancreatic cancer, CA 19–9 carbohydrate antigen 19–9, CAP score College of American Pathologists score